Atlas Trials

TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC

Clinical trial NCT04992143 · UNKNOWN

Trial details

NCT number
NCT04992143
Sponsor
First Affiliated Hospital of Zhejiang University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
BCLC Stage C Hepatocellular Carcinoma
Start date
2021-08-20
Primary completion
2023-08-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.